Skip to main content
. 2020 May 24;26:e923688-1–e923688-14. doi: 10.12659/MSM.923688

Figure 3.

Figure 3

Changes of the PGC-1α/SIRT3 pathway after LV-shRNA treatment. (A–E) The changes of PGC-1α/SIRT3 pathway after LV-shPGC-1α treatment in vivo. (F–J) The changes of PGC-1α/SIRT3 pathway after LV-shPGC-1α treatment in vitro. (** P<0.01, * P<0.05; n=6/group).